Search

Author/Creator Tullis, Elizabeth

1. The future of cystic fibrosis care: a global perspective. Issue 1 (January 2020)

Authors:
Bell, Scott C; Mall, Marcus A; Gutierrez, Hector; Macek, Milan; Madge, Susan; Davies, Jane C; Burgel, Pierre-Régis; Tullis, Elizabeth; Castaños, Claudio; Castellani, Carlo; Byrnes, Catherine A; Cathcart, Fiona; Chotirmall, Sanjay H; Cosgriff, Rebecca; Eichler, Irmgard; Fajac, Isabelle; Goss, Chri...
Journal:
Lancet
Issue:
Volume 8:Issue 1(2020)
Page Start:
65
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Does extensive genotyping and nasal potential difference testing clarify the diagnosis of cystic fibrosis among patients with single-organ manifestations of cystic fibrosis?. Issue 3 (21st October 2013)

Authors:
Ooi, Chee Y; Dupuis, Annie; Ellis, Lynda; Jarvi, Keith; Martin, Sheelagh; Ray, Peter N; Steele, Leslie; Kortan, Paul; Gonska, Tanja; Dorfman, Ruslan; Solomon, Melinda; Zielenski, Julian; Corey, Mary; Tullis, Elizabeth; Durie, Peter
Journal:
Thorax
Issue:
Volume 69:Issue 3(2014)
Page Start:
254
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial. Issue 3 (March 2022)

Authors:
Sutharsan, Sivagurunathan; McKone, Edward F; Downey, Damian G; Duckers, Jamie; MacGregor, Gordon; Tullis, Elizabeth; Van Braeckel, Eva; Wainwright, Claire E; Watson, Danie; Ahluwalia, Neil; Bruinsma, Bote G; Harris, Christopher; Lam, Anna P; Lou, Yiyue; Moskowitz, Samuel M; Tian, Simon; Yuan, Jas...
Journal:
Lancet
Issue:
Volume 10:Issue 3(2022)
Page Start:
267
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. Issue 10212 (23rd November 2019)

Authors:
Heijerman, Harry G M; McKone, Edward F; Downey, Damian G; Van Braeckel, Eva; Rowe, Steven M; Tullis, Elizabeth; Mall, Marcus A; Welter, John J; Ramsey, Bonnie W; McKee, Charlotte M; Marigowda, Gautham; Moskowitz, Samuel M; Waltz, David; Sosnay, Patrick R; Simard, Christopher; Ahluwalia, Neil; Xua...
Journal:
Lancet
Issue:
Volume 394:Issue 10212(2019)
Page Start:
1940
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. 1256. New Acquisitions of ET-12 Burkholderia cenocepacia in Adults With Cystic Fibrosis: Role of Whole Genome Sequencing in Outbreak Investigation. (26th November 2018)

Authors:
Blanchard, Ana C; Tadros, Manal; Tang, Lin; Muller, Matthew; Spilker, Theodore; Waters, Valerie; Lipuma, John; Tullis, Elizabeth
Journal:
Open forum infectious diseases
Issue:
Volume 5(2018)Supplement 1
Page Start:
S383
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

10. Clinical development of triple-combination CFTR modulators for cystic fibrosis patients with one or two F508del alleles. Issue 2 (17th June 2019)

Authors:
Taylor-Cousar, Jennifer L.; Mall, Marcus A.; Ramsey, Bonnie W.; McKone, Edward F.; Tullis, Elizabeth; Marigowda, Gautham; McKee, Charlotte M.; Waltz, David; Moskowitz, Samuel M.; Savage, Jessica; Xuan, Fengjuan; Rowe, Steven M.
Journal:
ERJ open research
Issue:
Volume 5:Issue 2(2019)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗